CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / ELI Lilly & CO (LLY) / mirikizumab
Forward catalyst · LLY

mirikizumab

Sponsor ELI Lilly & CO · listed as LLY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

mirikizumab is a clinical-stage drug asset sponsored by ELI Lilly & CO, listed as LLY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2027 (month precision, medium confidence), tied to trial NCT05509777. The asset is in Phase 3 and currently recruiting, studied in Crohn's Disease. It appears across 6 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-12-31
As disclosedDec 2027
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05509777
PhasePHASE3
StatusRECRUITING
Lead sponsorEli Lilly and Company
Listed asLLY
Condition(s)Crohn's Disease
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More LLY catalysts

Related catalysts and sponsor